FDA approves Watson's pain patch

Succeeding where others failed, Watson Pharmaceuticals got the FDA go-ahead to sell a generic version of Johnson & Johnson's Duragesic pain patch. With the patch, Watson will be jumping into a $1.2 billion market now divided among Duragesic and several other generic competitors.

- check out the release on the approval

Related Articles:
Watson to pay $1.9B for Andrx. Report
Bisaro handed reigns at Watson. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.